Atlas Trials

Shi Ming

8 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Shi Ming

RecordFirmDate
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T (NCT05760599)Shi Ming2023-02-27
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T (NCT05886257)Shi Ming2022-12-07
HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC (NCT04961970)Shi Ming2021-07-09
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection (NCT04044651)Shi Ming2019-10-30
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (NCT04044313)Shi Ming2019-08-01
Lenvatinib Plus PD-1 Antibody for Unresectable ICC (NCT03779100)Shi Ming2018-12-17
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria (NCT03775707)Shi Ming2018-12-01
HAIC Versus Systemic Chemotherapy for Unresectable ICC (NCT03771846)Shi Ming2018-08-01

Track Shi Ming automatically

Every clearance here is in the API, with alerts when new ones post.